Based on this evidence, platinum-based chemoradiotherapy following durvalumab treatment was recommended as first-line treatment for unresectable stage IIIB and IIIC NSCLC patients without EGFR or ALK mutations (12). The gene discussed is ALK; the disease is non-small cell lung carcinoma.